Dr Reddy's delays semaglutide supply due to active ingredient issue

• Certain batches of semaglutide were found to be out of specification, prompting an investigation into the active pharmaceutical ingredient quality issue
• Dr Reddy's did not specify the duration of supply delays or provide further details, though the company stated patient safety and regulatory filings remain unaffected
• More than half a dozen Indian drugmakers have launched lower-cost copies of Novo Nordisk's products, though demand plateaued in June according to Pharmarack research

Summary

Key Development:

Dr Reddy's Laboratories announced on Thursday, July 9, that it is delaying commercial supplies of semaglutide due to quality issues with the active pharmaceutical ingredient (API). Certain batches were found to be "out of specification," prompting an investigation into the root cause.

Companies and Products:

• Dr Reddy's has launched Obeda, a semaglutide injection for diabetes treatment in India
• Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Ozempic and Wegovy, used for diabetes and obesity
• Over half a dozen Indian drugmakers have introduced lower-cost versions of these medications

Market Impact:

Despite the supply delay, Dr Reddy's stock rose 1.8% following the announcement, while India's Nifty Pharma index gained 0.6%. The company emphasized there is no impact on patient safety or existing global regulatory filings.

Market Context:

Indian pharmaceutical companies have been aggressively competing in the semaglutide market, offering cheaper alternatives to Novo Nordisk's premium-priced products. However, research firm Pharmarack indicates that demand for these drugs plateaued in June, suggesting potential market saturation.

Outstanding Questions:

Dr Reddy's did not specify the duration of the supply disruption or provide additional details about the extent of the quality issues. The company is implementing measures to ensure product quality going forward.

This development highlights quality control challenges facing generic drugmakers entering the lucrative GLP-1 diabetes and weight-loss medication market, though investor confidence appears largely unshaken.